There are
nearly 300 medicines in clinical development to treat cardiovascular disease.
This new research report examines in detail the key areas of the cardiovascular
(CV) market, gathering inside opinion of cardiologists, to highlight the
dynamic changes that are underway in this multibillion dollar marketplace.
Successful
players will, necessarily, need to cannibalise their existing cardiovascular
franchises in order to limit the impact of generic erosion when their patents
expire, whilst at the same time investing in alternative therapies with better,
more efficacious outcomes. This is a significant challenge given the high
barrier to entry and unmet clinical needs. Not only is cardiovascular disease a
“Silent Killer”, it is also a commercial time bomb where the risk/reward ratio
for any company willing to participate needs to be carefully considered.
Complete Report Copy Available @ http://www.rnrmarketresearch.com/the-silent-killer-recent-advances-in-cardiovascular-disease-market-report.html
This
report provides you with a systematic appraisal into the current and future CV
market, including…
A detailed
review of the leading brands and how they are being positioned in the market,
in addition to the potential impact of generics
- Assessment
of key products in development, identifying ‘Ones to Watch’ in late-stage
clinical development where proof of concept data has been established
- Review
of products that are ‘Waiting in the Wings’ in early-stage clinical development
where Point-of-Care data is being gathered
- Analysis
of the potential of ‘Long Shots’ which represent new and innovative products
where the scientific rationale has yet to be fully tested
Antilipidemics
The
lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C)
and triglycerides (TGs) has been shown to reduce the chance of a heart attack
and death in people who have an elevated risk of developing heart disease or
who already have heart disease. Several drug classes are currently available to
treat a range of lipid disorders; each has a different mechanism of action,
safety profile and impact on blood lipid profiles to different degrees.
Key drugs covered by the report
include
- Leading
brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and
Partners), etc…
- Recent generics - Atorvastatin, etc…
- Ones to watch - Alirocumab (Sanofi/Regeneron
Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc…
- Waiting in the wings - RG 7652 (Roche), RN-316
(Pfizer), DRL-17822 (Dr Reddy), etc…
- Long shots - ALN PCS (Alnylam/The
Medicine Company), etc…
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=104306
Just some of the key questions
answered include
- Why are
statins the gold stand in lipid lowering therapies and which is the most
effective at lowering LDL-C?
- Will
AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin
reaches the market?
- Why are
PCSK9 inhibitors important to cardiologists and which drugs are leading the
field?
- Kynamro
approved in the US but not in Europe… what next?
- What new
HDL-C modulating therapies are in development?
- What new
products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?
Anticoagulants
Anticoagulant
therapy is the mainstay for the prevention and treatment of thrombotic
complications. Doctors commonly give patients anticoagulation therapy during
invasive procedures such as angioplasty or coronary stents as well as during
elective knee and hip replacement surgery and abdominal surgery where there is
an increased risk of blood clots. In addition, patients with an increased risk
of thrombosis and/or thromboembolism such as those with acute coronary syndrome
(ACS), those suffering with atrial fibrillation (AF; an erratic heart beat) or
those with a history of stroke, are often treated with anticoagulant medicines
to improve clinical outcomes.
Key drugs covered by the report
include
- Leading brands - Coumadin (Bristol-Myers
Squibb), Praxada (Boehringer Ingelheim), Xarelto (Bayer/Johnson & Johnson),
etc…
- Recent generics - Clopidogrel, Enoxaparin
sodium, etc…
- Ones to watch - Otamixaban (Sanofi),
Vorapaxar (Merck & Co.), etc…
- Waiting in the wings - Betrixaban (Portola
Pharmaceuticals)
- Long shots - EP217609 (EndotisPharma),
etc…
Just some of the key questions
answered include
- Have the
new OAPs changed the treatment paradigm for patients at high risk from stroke?
- Will
Effient maintain its head start or will the TRIOLOGY ACS trial cause it to
stumble?
- What
warfarin alternatives have entered the market?
- Boehringer
Ingelheim’s Pradaxa is first to the market but what safety issues have been
flagged up?
- Why has
GlaxoSmithKline’s Arixtra failed to impress?
- What new
anticoagulant drug classes are in development and who is leading the field?
Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=104306
Antihypertensives
High blood
pressure or hypertension is a highly prevalent cardiovascular risk factor which
is associated with an increased risk of heart attack and stroke. The
renin-angiotensin-aldosterone system (RAAS) is widely accepted as the key
pathway in the regulation of blood pressure and body volume and has been the
target for a cocktail of antihypertensive drugs that include angiotensin
receptor blockers (ARBs), angiotensin-converting-enzyme (ACE) inhibitors,
aldosterone antagonists and more recently the direct renin inhibitors (DRIs).
Key drugs covered by the report
include
- Leading
brands - Avapro (Sanofi/Bristol-Myers Squibb), Diovan (Novartis),
Edarbi (Takeda), etc…
- Recent generics - Irbesartan, etc…
- Ones to watch - LCZ696 (Novartis), etc…
- Waiting in the wings - DSP-9599 (Dainippon Sumitomo
Pharma), etc…
- Long shots - DARA (Retrophin), etc…
Just some of the key questions
answered include
- What
impact have generics had on the sale of Avapro?
- Why have
Diovan generics been slow off the mark and have pill combinations offered any
protection?
- Will
Takeda’s Edarbi become the new gold standard in a market dominated by generics?
- Why has
Tekturna not lived up to its promise, do direct renin inhibitors have a future?
- What
innovative DRIs are in clinical development?
- What new
drug classes are next in line to transform the antihypertensive market?
Explore More Report of Cardiovascular
Disease Drugs market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cardiovascular-disease-drugs
